210 related articles for article (PubMed ID: 19603023)
1. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.
Kahlert C; Weber H; Mogler C; Bergmann F; Schirmacher P; Kenngott HG; Matterne U; Mollberg N; Rahbari NN; Hinz U; Koch M; Aigner M; Weitz J
Br J Cancer; 2009 Aug; 101(3):457-64. PubMed ID: 19603023
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
3. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Wachowiak R; Mayer S; Kaifi J; Gebauer F; Izbicki JR; Lacher M; Bockhorn M; Tachezy M
Anticancer Res; 2016 Aug; 36(8):3991-5. PubMed ID: 27466504
[TBL] [Abstract][Full Text] [Related]
5. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
6. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
8. ALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy.
Sulaj A; Kopf S; Gröne E; Gröne HJ; Hoffmann S; Schleicher E; Häring HU; Schwenger V; Herzig S; Fleming T; Nawroth PP; von Bauer R
J Diabetes Complications; 2017 Jun; 31(6):1058-1065. PubMed ID: 28325697
[TBL] [Abstract][Full Text] [Related]
9. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.
Hansen AG; Arnold SA; Jiang M; Palmer TD; Ketova T; Merkel A; Pickup M; Samaras S; Shyr Y; Moses HL; Hayward SW; Sterling JA; Zijlstra A
Cancer Res; 2014 Mar; 74(5):1404-15. PubMed ID: 24385212
[TBL] [Abstract][Full Text] [Related]
10. ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression.
Ferragut F; Vachetta VS; Troncoso MF; Rabinovich GA; Elola MT
Cytokine Growth Factor Rev; 2021 Oct; 61():27-37. PubMed ID: 34272152
[TBL] [Abstract][Full Text] [Related]
11. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
[TBL] [Abstract][Full Text] [Related]
12. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.
Rosso O; Piazza T; Bongarzone I; Rossello A; Mezzanzanica D; Canevari S; Orengo AM; Puppo A; Ferrini S; Fabbi M
Mol Cancer Res; 2007 Dec; 5(12):1246-53. PubMed ID: 18171982
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients.
Sawhney M; Matta A; Macha MA; Kaur J; DattaGupta S; Shukla NK; Ralhan R
Int J Cancer; 2009 May; 124(9):2098-105. PubMed ID: 19142865
[TBL] [Abstract][Full Text] [Related]
14. Activated leukocyte cell adhesion molecule (ALCAM/CD166) expression in head and neck squamous cell carcinoma (HNSSC).
Clauditz TS; von Rheinbaben K; Lebok P; Minner S; Tachezy M; Borgmann K; Knecht R; Sauter G; Wilczak W; Blessmann M; Münscher A
Pathol Res Pract; 2014 Oct; 210(10):649-55. PubMed ID: 25028217
[TBL] [Abstract][Full Text] [Related]
15. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro.
Jin Z; Selaru FM; Cheng Y; Kan T; Agarwal R; Mori Y; Olaru AV; Yang J; David S; Hamilton JP; Abraham JM; Harmon J; Duncan M; Montgomery EA; Meltzer SJ
Oncogene; 2011 Mar; 30(13):1577-85. PubMed ID: 21119604
[TBL] [Abstract][Full Text] [Related]
17. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
18. ALCAM (CD166) expression and serum levels in pancreatic cancer.
Tachezy M; Zander H; Marx AH; Stahl PR; Gebauer F; Izbicki JR; Bockhorn M
PLoS One; 2012; 7(6):e39018. PubMed ID: 22745698
[TBL] [Abstract][Full Text] [Related]
19. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
20. Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.
Ihnen M; Köhler N; Kersten JF; Milde-Langosch K; Beck K; Höller S; Müller V; Witzel I; Jänicke F; Kilic E
Dis Markers; 2010; 28(2):71-8. PubMed ID: 20364042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
